Novel antiplatelet strategies in acute coronary syndromes
View Full Paper
Ask AI
Bookmark
Share
Key result
Prasugrel cuts major cardiovascular events ~19% versus standard clopidogrel in patients with ACS.
- HR 0.81
- 95% CI 0.73-0.90
- P<0.001
- NNT 46
Why the study?
Do novel antiplatelet strategies reduce ischemic events in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes (ACS)
Comparison
Novel antiplatelet agents and high-dose… vs Standard-dose clopidogrel or placebo
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports prasugrel in ACS; leaves open net clinical benefit optimization across real-world populations.
Structured PICO
Do novel antiplatelet strategies reduce ischemic events in patients with acute coronary syndromes?
P
Population
A review of novel antiplatelet strategies for acute coronary syndromes, highlighting the superior efficacy but higher bleeding risk of prasugrel compared to clopidogrel, alongside emerging agents like AZD6140 and cangrelor.
I
Intervention
Novel antiplatelet agents (prasugrel, AZD6140, cangrelor, SCH 530348) and high-dose clopidogrel
C
Comparator
Standard-dose clopidogrel or placebo
Main Result
Hazard Ratio: 0.81 (95% CI 0.73–0.9)
Absolute Event Rate: 9.9% vs 12.1%
Number Needed to Treat: 46
p-value: p=<0.001
Novel antiplatelet agents provide more potent and consistent platelet inhibition than standard clopidogrel, translating to reduced ischemic events but with a potential trade-off of increased bleeding risk.
Limitations
- Lack of head-to-head comparisons among novel agents
- Wide variability in how platelet aggregation studies are conducted
Cite This Study
Bhatt et al. (2009) conducted a review in Acute coronary syndromes. Novel antiplatelet strategies (e.g., prasugrel) vs. Clopidogrel was evaluated on Composite of cardiovascular death, MI, or stroke (TRITON-TIMI 38) (HR 0.81, 95% CI 0.73-0.90, p=<0.001). In the highlighted TRITON-TIMI 38 trial, prasugrel reduced the composite rate of cardiovascular death, myocardial infarction, or stroke by 19% (HR 0.81) compared with standard-dose clopidogrel in patients with acute coronary syndromes.
Topics
View Full Paper
Ask AI
Bookmark
Share